5728-45-0

Usage

Uses

Used in Pharmaceutical Synthesis:
4-(3-Cyanophenyl)benzoic acid is used as a precursor in the synthesis of various pharmaceuticals and organic compounds. Its unique structure allows it to be a key component in the development of new drugs and medicinal agents.
Used in Materials Science:
In the field of materials science, 4-(3-Cyanophenyl)benzoic acid has potential applications due to its chemical properties. It can be utilized in the creation of new materials with specific characteristics, such as improved stability or reactivity.
Used as a Chemical Reaction Reagent:
4-(3-Cyanophenyl)benzoic acid also serves as a reagent in chemical reactions, facilitating various processes in organic chemistry. Its presence can enhance reaction rates or provide specific outcomes that are otherwise difficult to achieve.

Upstream product

• 89900-92-5 methyl 3′-cyano-[1,1′-biphenyl]-4-carboxylate 
• 2113-57-7 3-bromobiphenyl 
• 5730-89-2 4-acetyl-3'-bromobiphenyl 
• 619-42-1 4-methoxycarbonylphenyl bromide 
• 150255-96-2 (3‐cyanophenyl)boronic acid 
• 6952-59-6 3-cyanobromobenzene 
• 14047-29-1 4-carboxyphenylboronic acid 
• 5737-83-7 3'-bromobiphenyl-4-carboxylic acid 
• 544-92-3 copper(I) cyanide 

Downstream Products

• 89900-92-5 methyl 3′-cyano-[1,1′-biphenyl]-4-carboxylate 

Relevant academic research and scientific papers

Lead discovery, chemical optimization, and biological evaluation studies of novel histone methyltransferase SET7 small-molecule inhibitors

The post-translational modifications of histones, including histone methylation and demethylation, control the expression switch of multiple genes. SET domain-containing lysine methyltransferase 7 (SET7) is the only methyltransferase, which can specifically monomethylate lysine-4 of histone H3 (H3K4me1) and play critical roles in various diseases, including breast cancer, hepatitis C virus (HCV), atherosclerotic vascular disease, diabetes, prostate cancer, hepatocellular carcinoma, and obesity. However, several known SET7 inhibitors exhibit weak activity or poor selectivity. Therefore, the development of novel SET7 inhibitors is highly desirable and of great clinical value. In this study, we identified 2–79 as a new hit compound by structure-based virtual screening and further AlphaLISA-based biochemical evaluation. Via chemical optimization, the synthesized compound DC21 was confirmed as a potent SET7 inhibitor with an IC50 value of 15.93 μM. The interaction between DC21 and SET7 was also validated through SPR experiment. Especially, DC21 retarded proliferation of MCF7 cells with an IC50 value of 25.84 μM in cellular level. In addition, DC21 has good selectivity for several other epigenetic targets, such as SUV39H1, G9a, NSD1, DOT1L and MOF. DC21 can serve as a lead compound to develop more potential SET7 inhibitors and as a chemical probe for SET7 biological function studies.

INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS

The present invention relates to compounds of Formula I: I which are agonists of the M-1 muscarinic receptor.

MUSCARINIC AGONISTS

The present invention relates to compounds of Formula (I): which are agonists of the M-1 muscarinic receptor.

MUSCARINIC AGONISTS

The present invention relates to compounds of Formula (I): which are agonists of the M-1 muscarinic receptor.

Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs

Anthranilamides 4 and 5 were designed and synthesized as selective and orally bioavailable factor Xa inhibitors. Structural modifications aimed at lowering their lipophilicity were performed at the central phenyl ring and at the S4 binding biphenyl region by incorporating water solublizing substituents. The resulting compounds (e.g., 7, 8, 14, 30a, and 32b) are highly potent in vitro, and show improved activity in human plasma-based thrombin generation assay.

The Effects of Substituents on the Rate of Saponification of Biphenyl-4-carboxylates

Second-order rate constants have been measured for the saponification of methyl 2'-, 3'-, and 4'-substituted biphenyl-4-carboxylates at several temperatures in 85percent (w/w) methanol-water and activation parameters have been calculated.The Hammett equation applies very well to the saponification of 3'- and 4'-substituted biphenyl-4-carboxylates with ?-constants evaluated by the FMMF method.The effect of 2'-substituents is understandable in terms of ?-electron steric effects.